Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07246447

Ketodex Versus Opioid Based Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy.

comparing Opioid sparing anesthesia using ketodex versus opioid based anesthesia in obese patients undergoing laparoscopic sleeve gastrectomy.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cairo university hospitals

Cairo, Manial, 11965, Egypt

About this study

Bariatric surgery has seen a substantial increase, especially among patients with medically complex obesity who struggle to lose weight with traditional approaches . Although advances in anesthetic procedures enhance surgical and clinical outcomes, regular opioid usage in bariatric surgeries might result in adverse effects such as drowsiness, postoperative nausea and vomiting (PONV), respiratory depression, and impaired gastrointestinal motility. These adverse effects increase the risk of postoperative cardiac and respiratory complications .

The key to managing such patients is the utilization of a novel form of anesthesia and analgesia, known as opioid-sparing anesthesia, which has recently been developed to ensure better outcomes . During opioid-sparing anesthesia, the sympathetic nervous system is inhibited by means other than opioid delivery . Such techniques include the use of medications from the alpha-2 agonist group, lidocaine, ketamine, magnesium sulfate, beta-blockers, or gabapentinoids .

Ketamine is an N-methyl-D-aspartate antagonist with analgesic and anti-hyperalgesic properties at low doses . This drug prevents the development of opioid tolerance by minimizing opioid use while reducing postoperative pain, ultimately decreasing opioid-related postoperative morbidity .

Dexmedetomidine, a highly selective α2-adrenoceptor agonist, is used as an adjuvant analgesic in the perioperative period . It improves hemodynamic stability and reduces the stress induced by intubation due to its central sympatholytic action . Furthermore, it decreases the need for opioids and anesthetics, providing additional benefits for obese patients .

By lowering the required dosages, adding a low dose of ketamine to dexmedetomidine is thought to result in less toxicity than using either medication alone . Vishnuraj et al. concluded that the combination of ketamine and dexmedetomidine effectively reduced postoperative opioid consumption; however, their approach involved the use of ketamine as a bolus following induction, in conjunction with a continuous infusion of dexmedetomidine in adults undergoing laparoscopic cholecystectomy .

To the best of our knowledge, the use of both ketamine and dexmedetomidine infusion versus opioid-based anesthesia among patients undergoing bariatric surgery, specifically regarding postoperative pain, has not been previously compared

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (>18 years) undergoing Elective Bariatric Surgery .
  • American Society of Anesthesiologists physical status class II or III .
  • body mass index (BMI) > 35 kg/m2 .

Exclusion criteria

  • • Refusal to participate .
  • Any sensitivity or contraindication to ketamine or dexmedotomidine .
  • Pregnancy or breast feeding .
  • Patients with significant renal impairment .
  • Any patient on regular intake of beta blockers or calcium channel blockers .
  • CNS disorders eg: seizures , raised intra cranial tension .
  • Chronic opioid use.
  • Obese patients with STOP bang score more than 5 .

Treatment and study plan

ketamine and dexmeditomidine combination

Drug

Group KD: Two syringes containing ketodex-ketamine (1 mg/kg) and dexmedetomidine (1 µg/kg)-each diluted with 0.9% saline and infused over 10 minutes. Maintenance will consist of continuous low-dose infusion of ketamine (0.3 mg/kg/h) and dexmedetomidine (0.5 µg/kg/h) in separate syringes until 15 minutes before the end of surgery.

Other names: ketodex

Fentanyl (IV)

Drug

Group OP: Two syringes-one containing fentanyl (2 µg/kg) and the other 0.9% saline-infused over 10 minutes. Maintenance will be provided by two continuous saline infusions, prepared to mimic the ketodex infusions, until 15 minutes before the end of surgery.

Other names: opioiod based anesthesia

Primary outcomes

  1. Total nalbuphine consumption (mg) during the first 24 hours postoperatively.

    Time frame: during the first 24 hours postoperatively

    Total nalbuphine consumption (mg) during the first 24 hours postoperatively.

Secondary outcomes

  1. Total intraoperative titrated fentanyl dose for each patient.

    Time frame: intraoperative time

  2. Time to extubation, defined as the interval between discontinuation of anesthesia and tracheal extubation

    Time frame: the interval between discontinuation of anesthesia and tracheal extubation

  3. • Time to first postoperative rescue analgesia

    Time frame: during 1st 24 hrs postoperatively.

  4. Postoperative sedation scores.

    Time frame: 1st 24 hours postoperatively

    Sedation assessment: All patients will be monitored postoperatively in the post-anesthesia care unit (PACU) and ward. Sedation will be assessed using the Modified Observer's Assessment of Alertness/Sedation Scale (MOASS) . Scores will be recorded at 0, 10, 30, and 60 minutes from PACU admission.

  5. Postoperative pain scores assessed using the Numerical Rating Scale (NRS).

    Time frame: 1st 24 hours post operatively

    Postoperative pain: Pain will be assessed using the Numerical Rating Scale (NRS, 0 = no pain, 10 = worst pain). Patients will be instructed preoperatively regarding the scale. NRS scores will be recorded at 0, 30, and 60 minutes, and at 2, 6, 12, and 24 hours after surgery.

  6. Postoperative nausea and vomiting (PONV) scores

    Time frame: 1st 24 hours postoperatively

    by using Simplified PONV Impact Scale (SPONVIS) This simplified version, often used for audit and post-discharge review, uses just two main components: Nausea Impact and Vomiting Impact.

    • Nausea Impact," Based on the patient's assessment of how much the nausea affected their recovery (e.g., ability to eat, walk, or be discharged).","0 to 5 Points (e.g., 0 = No Impact, 5 = Severe Impact/Required hospital stay)"
    • Vomiting/Retching, Total number of vomiting or retching episodes.,"0 to 5 Points (e.g., 0 = None, 5 = ≥3 episodes)" Total SPONVIS Score Sum of Nausea Impact + Vomiting/Retching Points, Score: 0 to 10 Cut-off for CIPONV Total Score ≥5
  7. Patient satisfaction scores .

    Time frame: during 1st 24 hours postoperatively.

    (0 = not satisfied, 10 = highly satisfied).

  8. Length of hospital stay

    Time frame: 1-2 weeks

    From date of randomization until the date of first documented progression

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Collaborators

  • Kasr El Aini Hospital

Registry information

Official study title

Opioid Sparing Anesthesia Using Ketodex Versus Opioid Based Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy: A Randomized Controlled Trial.

Acronym: Ketodex

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 24, 2025
Registry last updated
Apr 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.